Session » Pediatric Rheumatology – Clinical Poster III: Other

Date: Monday, November 14, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1936

A De Novo Dominant-negative PSMB8 mutation is Linked to a More Severe CANDLE-like Phenotype

1:00PM-3:00PM: Abstract Number: 1937

Adult Rheumatologists’ Knowledge, Comfort Level, and Perceived Barriers in Supporting Newly Transitioned Youth with Chronic Rheumatic Diseases in Canada

1:00PM-3:00PM: Abstract Number: 1926

Analysis of New Patient Referrals to a Large Pediatric Rheumatology Clinic

1:00PM-3:00PM: Abstract Number: 1930

Assessing the Number of Children Evaluated for Recurrent Fevers During the COVID-19 Pandemic in North America

1:00PM-3:00PM: Abstract Number: 1925

Characterizing Phenotypic Changes by SARS-CoV-2 Variant in Multisystem Inflammatory Syndrome in Children (MIS-C): A Single Institution Case Series

1:00PM-3:00PM: Abstract Number: 1948

Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort

1:00PM-3:00PM: Abstract Number: 1938

Current Approach to COVID-19 and Other Vaccinations in Children with Previous Multisystem Inflammatory Syndrome (MIS-C): An International Survey

1:00PM-3:00PM: Abstract Number: 1944

Description and Delays in Care in the Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program

1:00PM-3:00PM: Abstract Number: 1945

Determinants of Patient’s Global Assessment of Disease Severity and Predictors of Disease Course in Juvenile Fibromyalgia

1:00PM-3:00PM: Abstract Number: 1949

Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine Among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases

1:00PM-3:00PM: Abstract Number: 1932

Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients

1:00PM-3:00PM: Abstract Number: 1946

Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile

1:00PM-3:00PM: Abstract Number: 1940

Genetic Variants and Cytokine Signatures in Patients with Syndrome of Undifferentiated Recurrent Fevers

1:00PM-3:00PM: Abstract Number: 1928

Idiopathic Pulmonary Capillaritis Within the Spectrum of Pediatric Diffuse Alveolar Hemorrhage

1:00PM-3:00PM: Abstract Number: 1942

Maybe Silent: Spine Disease in Chronic Recurrent Multifocal Osteomyelitis, Clinical Features, Risk Factors, and Red Flags

1:00PM-3:00PM: Abstract Number: 1947

Medication Use in Childhood Sjogren Disease

1:00PM-3:00PM: Abstract Number: 1931

NOD2 Mutations Are Associated with Upregulated Type 1 Interferon Gene Expression and Development of Granulomatous Hepatitis in Children with Autoimmune Hepatitis

1:00PM-3:00PM: Abstract Number: 1929

Outcomes and Safety of Anakinra for the Treatment of Multisystem Inflammatory Syndrome in Children

1:00PM-3:00PM: Abstract Number: 1927

Patient and Parent Perceptions of an Established Rheumatology Transition Clinic for Adolescents and Young Adults

1:00PM-3:00PM: Abstract Number: 1933

PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results

1:00PM-3:00PM: Abstract Number: 1941

Pediatric Idiopathic Pulmonary Hemosiderosis – a Single-Center, Retrospective Study Comparing Use of Commonly Used Steroid-Sparing Agents

1:00PM-3:00PM: Abstract Number: 1943

Prevalence and Evolution of Undifferentiated Periodic Fever Syndromes in an Academic Pediatric Rheumatology Practice

1:00PM-3:00PM: Abstract Number: 1935

Racial Disparities Influence Healthcare Utilization in Pediatric Rheumatology Clinic

1:00PM-3:00PM: Abstract Number: 1924

Reading the Waves: Identifying Distinct Phenotypes of Multisystem Inflammatory Syndrome in Children During the 2020-2021 COVID-19 Pandemic

1:00PM-3:00PM: Abstract Number: 1939

Safety and Humoral Response Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-onset Autoimmune Inflammatory Rheumatic Diseases

1:00PM-3:00PM: Abstract Number: 1934

Transition Readiness Before versus After Adolescents with Rheumatic Disease Transition to Adult Care

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].